Menelas Pangalos - AstraZeneca PLC Executive Vice President - Innovative Medicines

AZNCF Stock  USD 151.16  0.70  0.47%   

President

Mr. Menelas Pangalos is an Executive Vice President Research Development BioPharmaceuticals of AstraZeneca PLC. He was appointed as Executive VicePresident, RD BioPharmaceuticals in January 2019 and is responsible for RD from discovery through to latestage development for CVRM and Respiratory. Prior to this, he served as Executive VicePresident of AstraZenecas IMED Biotech Unit and Global Business Development. Since joining AstraZeneca in 2010, Mene has led a transformation of our RD productivity and has championed an open approach to working with academic and other external partners. Mene previously held senior RD roles at Pfizer, Wyeth and GSK. Mene holds an Honorary PhD from Glasgow University and is a Fellow of the Academy of Medical Sciences, the Royal Society of Biology and Clare Hall, University of Cambridge. He sits on the Medical Research Council, cochairs the Life Sciences Council Expert Group on Innovation, Clinical Research and Data and is a member of the Life Sciences Industrial Strategy Implementation Board and National Genomics Board. He is also a Board member of the British Pharmaceutical Group and Cambridge Universitys Judge Business School. since 2019.
Age 56
Tenure 6 years
Professional MarksPh.D
Phone44 20 3749 5000
Webhttps://www.astrazeneca.com

AstraZeneca PLC Management Efficiency

The company has return on total asset (ROA) of 0.0531 % which means that it generated a profit of $0.0531 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0863 %, meaning that it generated $0.0863 on every $100 dollars invested by stockholders. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities.
AstraZeneca PLC has accumulated 22.96 B in total debt with debt to equity ratio (D/E) of 0.87, which is about average as compared to similar companies. AstraZeneca PLC has a current ratio of 0.94, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist AstraZeneca PLC until it has trouble settling it off, either with new capital or with free cash flow. So, AstraZeneca PLC's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like AstraZeneca PLC sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for AstraZeneca to invest in growth at high rates of return. When we think about AstraZeneca PLC's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 9 records

PRESIDENT Age

Hiroyuki OkuzawaDaiichi Sankyo
61
Alberto RouraGrifols SA ADR
65
Miguel MontblanchGrifols SA ADR
64
Sergio AdellGrifols SA ADR
57
Yoshitsugu ShitakaAstellas Pharma
N/A
David BellGrifols SA ADR
71
Antonio MartinezGrifols SA ADR
58
JeanBaptiste ChatillonSanofi ADR
59
Yoshitsugu ShitakaAstellas Pharma
N/A
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. Astrazeneca Plc operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 83100 people. AstraZeneca PLC [AZNCF] is a Pink Sheet which is traded between brokers over the counter.

Management Performance

AstraZeneca PLC Leadership Team

Elected by the shareholders, the AstraZeneca PLC's board of directors comprises two types of representatives: AstraZeneca PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AstraZeneca. The board's role is to monitor AstraZeneca PLC's management team and ensure that shareholders' interests are well served. AstraZeneca PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AstraZeneca PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
Marc Dunoyer, CFO and Executive Director
Chris Sheldon, Head Relations
Pam Cheng, Executive Vice-President of Operations and Information Technology
MBA DVM, CEO Director
Gonzalo Vina, Head Relations
Aradhana MD, CFO Director
Menelas Pangalos, Executive Vice President - Innovative Medicines
Katarina Ageborg, Chief Compliance Officer
Jeffrey Pott, General Counsel
Ruud Dobber, Executive Vice President Europe

AstraZeneca Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is AstraZeneca PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Other Information on Investing in AstraZeneca Pink Sheet

AstraZeneca PLC financial ratios help investors to determine whether AstraZeneca Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca PLC security.